Advanced Oncotherapy - Presentation highlights superiority of LIGHT

Advanced Oncotherapy

27/10/2022 07:31

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221027:nRSa3122Ea&default-theme=true

RNS Number : 3122E  Advanced Oncotherapy PLC  27 October 2022

Prior to publication, the information contained within this announcement was
deemed by the Company to constitute inside information as stipulated under the
UK Market Abuse Regulation. With the publication of this announcement, this
information is now considered to be in the public domain.

 

27 October 2022

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

ASTRO presentation highlights potential superiority of LIGHT over Gamma Knife,
photon or cyclotron-based proton therapy systems for the treatment of brain
tumours

 

Advanced Oncotherapy (AIM: AVO), the developer of LIGHT, the next generation
proton therapy system for cancer treatment, is pleased to announce that
findings of a modelling study led by the Company's research partner, the
Cleveland Clinic, were presented yesterday at the American Society for
Radiation Oncology ("ASTRO") 2022 Annual Meeting held in San Antonio, USA(1).

 

The research quantitatively compared treatment plan quality from different
proton systems, including LIGHT, and photon systems such as Gamma Knife
radiosurgery(2) for the irradiation of brain metastases. The findings support
the potential of LIGHT to deliver superior results in the treatment of such
tumours, as a result of the fast delivery time and precision that minimises
the damage to surrounding healthy tissues.

 

The study detailed the treatment planning of brain metastases for 35 brain
lesions from 20 patients. The researchers developed treatment plans using
cyclotron and LIGHT proton systems as well as the photon systems. The study
results indicated that the dose differential between radiation delivered to
the tumour compared to surrounding healthy brain dose was significantly
improved with the LIGHT system compared to the cyclotron and photon systems:

·    Dose differential between tumour and healthy tissue is a key quality
parameter for such treatment. Quantitatively, the average dose to the healthy
tissue in the entire brain was reduced between 17%-44% with the LIGHT system.

·   The LIGHT treatment plan enabled, on average, 58% faster dose delivery
compared to the cyclotron treatment plan. This speed advantage was due to the
ultra-fast energy switching time of 5 milliseconds that is uniquely possible
with the LIGHT system.

 

Dr Jonathan Farr, Chief Clinical Officer at Advanced Oncotherapy said:

"We were pleased to present results of research led by our partner, the
Cleveland Clinic, at the ASTRO conference. The modelling study shows that
linear accelerator proton beams have the potential to outperform both
photon-based and cyclotron-generated proton beams modalities in the treatment
of small brain tumours, as their precision and fast proton delivery time
minimises damage to surrounding healthy tissues.

 

"We believe the LIGHT system is set to be the most versatile proton therapy
system available. As this modelling study shows, it is ideally positioned to
deliver precisely both linear accelerator proton beams and linear accelerator
proton mini-beams. In addition, it has great potential to provide cutting edge
treatment protocols such as scanned, conformal FLASH radiotherapy. With our
first commercial LIGHT accelerator now generating a 230MeV beam, Advanced
Oncotherapy will continue to work with our research partners as we move
towards treating our first patients, which we expect in the second half of
2023."

 

- ENDS -

 

 

 Advanced Oncotherapy plc                                  www.avoplc.com (http://www.avoplc.com)
 Dr. Michael Sinclair, Executive Chairman                  Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Piers Shimwell (Corporate Finance)         Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales and Corporate Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                              Tel: +44 (0) 1483 413 500
 Jon Levinson                                              Tel: +44 (0) 20 3871 4066

 FTI Consulting (Financial PR & IR)                        advancedoncotherapy@fticonsulting.com
                                                           (mailto:advancedoncotherapy@fticonsulting.com)
 Simon Conway / Rob Winder                                 Tel: +44 (0) 20 3727 1000

 

 

Notes to Editors

1- American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting held in
San Antonio, USA. The presentation is entitled "Can Proton Linear Accelerator
Beams and Minibeams Achieve Superior Plan Quality over Cyclotron-Generated
Proton Beams and Photons in the Treatment of Multiple Brain Metastases?," T.
Gray, A.M. Kolano, L. Chieh-Wen, J.D. Donaghue, Y.B. Cho, J.B. Farr, P. Xia,
International Journal of Radiation Oncology, Biology, Physics 114, e572-e573
(2022)

 2- Gamma Knife is a focused array of photon beams for treating brain tumours

 

About Advanced Oncotherapy Plc

 

Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQDLBLLBLFFBL